Australia praised after rejecting biologic suffix

Adecision by Australia’s Therapeutic Goods Administration (TGA) to not use specific identifier suffixes as part of naming conventions for biologics has been welcomed by the global generics and biosimilars industry. Following a stakeholder consultation, the TGA said it had decided to “maintain the existing naming convention for biological and biosimilar medicines – that is continue using the Australian biological name, without a specific identifier suffix – and strengthen our adverse event reporting”.

Adecision by Australia’s Therapeutic Goods Administration (TGA) to not use specific identifier suffixes as part of naming conventions for biologics has been welcomed by the global generics and biosimilars industry. Following a stakeholder consultation, the TGA said it had decided to “maintain the existing naming convention for biological and biosimilar medicines – that is continue using the Australian biological name, without a specific identifier suffix – and strengthen our adverse event reporting”.

The TGA said it had made its decision in response to “broad stakeholder support for additional mechanisms to collect information...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By 

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.